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ABSTRACT  
 
Breast cancer is the most common kind of cancer affecting women 
worldwide, with approximately 1.67 million new cancer cases diagnosed in 
2012, which accounts for 25% of all cancers. On average, 1 in 8 women 
develop breast cancer during their lifetime. 
In this work, results from a case-control study on breast cancer in 
Portuguese patients, recruited by the Research Unit in Human Molecular 
Genetics, Lisbon, Portugal, were analysed. DNA extraction and genotyping 
were performed in the Laboratory of Pharmacogenomics and Molecular 
Toxicology, Centre for Biomedical Research (CBMR), University of Algarve. 
Polymerase chain reaction-restriction fragment length polymorphism (PCR-
RFLP) of a selected polymorphism in the Pregnane X receptor was employed in 
order to evaluate the potential role of this receptor in the susceptibility to the 
disease. 
PXR allelic and genotype frequencies in individuals with and without 
breast cancer were analysed by means of Chi-square (χ2) testing and 
calculation of Odds Ratios. According to the obtained results, there is a 
negative association of the PXR genotype A/A with breast cancer, and a 
positive association of the A/G genotype with the disese, with a 95% confidence 
level. On the other hand, the genotype G/G and the the alleles A and G 
considered individually have no significant association with the disease. 
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1. INTRODUCTION 
 
1.1. Breast Cancer 
 
Breast cancer is the second most common cancer in the world and, by far 
the most frequent cancer among women with an estimated 1.67 million new 
cancer cases diagnosed in 2012, which accounts for 25% of all cancers. A 
slight majority of cases occur in women in less developed regions. Incidence 
rates vary nearly fourfold across the world regions, with rates ranging from 27 
per 100,000 in Middle Africa and Eastern Asia to 96 in Western Europe. Breast 
cancer is the fifth cause of death from cancer overall (522,000 deaths) and 
while it is the most frequent cause of cancer death in women in less developed 
regions (324,000 deaths, 14.3% of total), it is now the second cause of cancer 
death in more developed regions (198,000 deaths, 15.4%) after lung cancer 
(Figure 1). [1] 
 
Figure 1. Estimated numbers (thousands) of new cancer cases (incidence) and deaths (mortality) in 
women in more developed and less developed regions of the world in 2012. Taken from [1]. 
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On average, one in eight women develops breast cancer during lifetime. 
Even if it is detected at an early stage, it still remains the second most common 
cause of cancer-related death in females after lung cancer. In spite of the 
advances over the last two decades in cancer diagnosis and treatments, breast 
cancer is still associated with high mortality and is a global health concern in 
both developed and developing countries. Previously to the year 2000, the 
incidence of breast cancer grew gradually since 1980. However, the rate 
reached a plateau between 2000 and 2003 for women of all ages, which 
coincides with the widespread use of mammograms as a standard screening 
method. Particularly, within this period, the incidence of breast cancer 
decreased dramatically among women between 50–69 years of age. This 
decrease has been associated with the reduced use of hormone replacement 
therapy in post-menopausal women during the early 2000s. [2]  
 
1.1.1. Types of Breast Cancer  
 
There are many risk factors that may be associated with breast cancer 
prevalence, which can affect the development and progression of the disease. 
Moreover, there are different types of breast cancer, which are described in this 
section. The majority of the cases are classified as either In Situ or Invasive, as 
represented in Figure 2. 
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Figure 2. Schematic division of the major types of breast cancer. 
 
 
1.1.1.1.  Carcinoma In Situ 
 
Lobular Carcinoma In Situ (LCIS). Lobular carcinoma In Situ is located in 
the milk-producing glands (lobules) of the breast (Figure 3). Although it is not a 
cancer, being diagnosed with LCIS indicates an increased risk of developing 
breast cancer. It consists of an uncommon condition in which abnormal cells 
form in the breast lobules or milk glands, and is most commonly found in pre-
menopausal women between the ages 40 and 50. [3] 
INTRODUCTION 
4 
 
 
Figure 3. Lobular Carcinoma In Situ (LCIS). Taken from [4]. 
 
Ductal Carcinoma In Situ (DCIS). Ductal carcinoma in situ is considered the 
earliest form of breast cancer. It consists on the presence of abnormal cells 
located in the milk ducts of the breast (Figure 4). DCIS is non-invasive, 
meaning that it does not spread out of the milk duct in other parts of the breast. 
DCIS is usually found through a mammogram, as part of breast cancer 
screening. Most cases of DCIS (~98%) do not become metastatic. However, 
around 50% evolve to invasive breast cancer (IBC). Most cases of DCIS are 
effectively treated with surgery and radiation. [3] 
 
Figure 4 Ductal and Lobular Carcinoma In Situ (DCIS). Taken from [2] 
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1.1.1.2.  Invasive Breast Carcinoma 
 
Invasive Lobular Carcinoma (ILC). Invasive Lobular Carcinoma (ILC) 
develops in the milk-producing glands (lobules) of the breast (Figure 5). ILC is 
able to advance to other parts of the body (mostly bone, brain, liver, and lungs), 
either through the bloodstream or the lymphatic system. ILC usually presents 
itself as an abnormal feeling in the breast (most often a thickening) and not as a 
hard mass that can be felt. Also, it is less likely to be detected in a 
mammogram. Women over the age of 40 have an increased risk of developing 
this kind of carcinoma, with most cases occurring at ages ranging 45-56. [3] 
 
Figure 5. Invasive Lobular Carcinoma (ILC). Taken from [4]. 
 
Invasive Ductal Carcinoma (IDC). Invasive Ductal Carcinoma (IDC) is the 
most frequent type of invasive breast cancer, and is responsible for nearly 85% 
of the cases. IDC initiates in the milk ducts and grows into the surrounding 
tissue (Figure 6), being able to spread into other parts of the body, such as 
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bone, brain, liver and lungs, through the bloodstream or the lymphatic system. 
This kind of carcinoma is characterized by a hard lump that usually is detected 
a spiked mass on a mammogram.  Women over the age of 40 have an 
increased risk of developing IDC, with around 50% of cases occurring in women 
over the age of 65. [3] 
 
Figure 6. Invasive Ductal Carcinoma (IDC). Taken from [4]. 
 
 
1.1.2. Risk Factors 
 
This big regional variation in breast cancer incidence rates is affected by a 
number of factors particularly related to lifestyle. A low number of children, 
giving birth at an older age, and lower acceptance of breastfeeding are some 
characteristics of women in more developed countries which are associated 
with the risk of breast cancer. [5] 
Prospective studies have shown that a high risk of breast cancer is 
associated with early menarche, late menopause, obesity in postmenstrual 
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women, and high concentrations of endogenous estradiol. Reduction of risk is 
associated with childbearing, and especially with a greater protection from an 
early first birth or a larger number of births. Also, breastfeeding is a protection 
against breast cancer. Moreover, a small increase in breast cancer risk can 
arise from both oral contraceptives and hormonal therapy for menopause, which 
can be low once the using is stopped. Alcohol also increases the risk, whereas 
physical activity is assumed to be protective. Mutations in certain genes greatly 
increase breast cancer risk; however, these seem to account for a minority of 
cases. [6] A detailed list of the studied risk factors is presented below: 
 
Age. While in reproductive years, breast cancer incidence seems to grow until 
women reach menopause; afterwards, over the age of 50, the rate is slower. 
 
Menarche and the menstrual cycle. The risk of breast cancer decreases as 
the age of menarche increases (5% per year of delay). Other menstrual factors, 
such as cycle length and regularity, have not been consistently related to risk of 
breast cancer. 
 
Childbearing. Childbearing has a dual effect on breast cancer risk, increasing 
in the period immediately right after a birth. However, this risk decreases 
gradually, and in long-term, bearing children has a protective effect against the 
disease. Women with at least one full-term pregnancy have, on average, 
around 25% reduction in breast-cancer risk. Moreover, an increased protection 
is observed as the number of pregnancies increases, reaching 50% risk with 
five or more children. Also, the risk of breast cancer can be lower as younger is 
the age of first birth. 
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Breastfeeding. The longer the time of breastfeeding, the higher will be the 
protection against breast cancer. Studies have revealed that women that have 
breastfed for total of 25 months have lowered the risk in about 33%. Also, the 
protective effect of breastfeeding is higher in younger than older women. 
 
Menopause. Breast cancer risk can be higher for the women who have the 
menopause at older ages, with an increase of 3% for per year. Also, the risk is 
higher in premenopausal than in postmenopausal women with the same age. 
 
Endogenous hormones. Studies have revealed that there is a positive 
association between the concentrations of serum oestradiol and risk of breast 
cancer in postmenopausal women. However, there is insufficient data for 
conclusions. Other sex hormones have been studied and it has been 
demonstrated that they also have positive associations with the risk of breast 
cancer.  
 
Oral contraceptives. The risk of breast cancer is increased by around 25% in 
oral contraceptive users. However, this increased risk drops after cessation of 
use, with no significance increase of risk after ten or more years after the use 
stops. Also, the use of oral contraceptives at older ages increases the risk of the 
disease. 
  
Hormonal therapy for the menopause. Women who are regular users of 
therapy with hormones have a higher risk of breast cancer than women who 
have never done these therapies.  
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Diet. In the countries with high-fat diet, the breast cancer risk has higher rates. 
 
Alcohol and smoking. Provisional studies have repeatedly demonstrated that 
alcohol drinking is related with a moderate rising of the risk of breast cancer. A 
consumption of around 30 g alcohol (3 units) per day is related with an increase 
of about 30% in breast-cancer risk. Many studies on the relation between 
smoking and breast-cancer risk have been performed; however, overall there is 
no association. 
 
Anthropometry. There seems to be a positive association between the height 
and the risk of breast cancer, with a 10% increase in risk for each 10 cm in 
height. However, the reasons for this association have not been established yet. 
Obesity increases the risk by 50% in postmenopausal women, on the other 
hand, in postmenopausal women, obesity seems to be protective. Some studies 
reported that the weight of birth is associated with the risk of breast cancer. This 
is related to factors such as hormone concentration during intrauterine life. 
 
Exercise. Based in many studies, a lower risk of breast cancer is related to 
lightly physical activity. Few hours of activity during the week can reduce the 
risk of breast cancer around 30%. 
 
Ionising radiation. Studies have revealed that the breast tissue is among the 
most sensitive tissues to the effects of ionising radiation. Also, studies on 
women younger than 40 reveal that a higher risk is observed with exposition. 
The negative effect of exposition can be the same for single or multiple 
exposures of the same dose. 
INTRODUCTION 
10 
 
Electromagnetic fields. Some studies suggest that being exposed to low dose 
of frequency electromagnetic fields and to artificial light at night may have been 
factors that can contributed in the increasing the incidence of breast cancer 
worldwide on the 20th century. However, the evidences are not persuasive. 
 
Environmental estrogens. Some man-made chemicals, such as 
organochlorines or polychlorinated biphenyls, have structural similarities to 
endogenous estrogens and can bind to the estrogen receptors. Several 
prospective studies have been performed to examine the possible associations 
of these substances with breast-cancer risk; however, the results have not 
shown any association. 
 
Family history and genetics. Apparently, environmental and lifestyle factors 
account for the most cases of breast cancer. Most women with the disease do 
not have a family history of it, and most women with affected relatives never 
develop it. On most studies on familial risk of breast cancer was found that, the 
risk is slightly higher for first-degree relatives (mothers, sisters, daughters), than 
with affected second-degree relatives (grandmothers, aunts, grand-daughters). 
However, the familial risk can be attributed both to share genes and to share 
physical environments and lifestyles. 
 
High-risk mutations. Have been identified and localised at least five germline 
mutations that predispose to breast cancer. These include mutations in the 
genes BRCA1, BRCA2, P53, PTEN, and ATM. Mutations in BRCA1 and 
BRCA2 can cause high risks of breast cancer, and especially ovarian cancer. 
[6] 
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1.1.3. Treatments of breast cancer 
 
The most common treatments for patients with breast cancer are surgery, 
radiotherapy and chemotherapy. The choice depends on several factors such 
as type of breast cancer, stage of evolving, location and especially the health 
status of the patient. Usually the goal of most of the treatment is to kill or to 
remove the cancer cells. Most of the treatments are applied in combination, 
either simultaneously or sequentially and the decision on which treatment is 
applied usually agreed between doctor and the patient. [7] The common types 
of cancer treatments are described shortly below: 
 
Surgery: Usually is the treatment for many solid tumours. Surgery can be 
applied in the case of benign breast cancer when the disease is detected in the 
early stage. The goal is to remove all cancerous cells from the patient. 
 
Radiation: The goal of radiation is to kill the cancer cells directly by damaging 
them with high energy beams. It can be applied in combination with surgery or 
drug treatment. 
 
Chemotherapy: The goal of chemotherapy is to damage the dividing cells and 
to protect additional reproduction. Drug chemotherapy is a batch of drugs that is 
used to kill cancer cells.  
 
Hormonal Treatments: These drugs are designed to prevent cancer cell 
growth by preventing the cells from receiving signals necessary for their 
continued growth and division. 
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Targeted Therapy: The goal of this treatment is to target the specific proteins 
and processes which are limited to cancer cells. The inhibition of these 
processes prevents the growth of cancer cell and division. This drug treatment 
is relatively new as a cancer treatment method. 
 
Antibodies: The goal is to attack cancer cells where the mechanism of 
antibodies is to take away the cancer cells or causing the direct death of cells. 
Because antibodies are naturally appearing proteins in our body, they can be 
used as treatment against cancer and are manufactured for use as drugs. 
Because of their specificity, antibodies may be regarded as a type of specific 
inhibitor. 
 
Biological Response Modifiers: These treatments involve the use of naturally 
occurring normal proteins that stimulate the body’s own defences against 
cancer. 
 
Vaccines: Vaccines include proteins found or produced by cancer cells. The 
aim of those proteins is to increase the body response against the cancer cells. 
The goal of cancer vaccines is to activate the protection of the body against 
cancer.  
 
Complementary and Alternative Medicines: These treatment methods are 
not practiced by conventional western medicine. They can include herbal, 
animal derived, and mind-body approaches of treating cancer. [8,9] 
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1.1.4. Variability in response 
 
In oncology, the treatment with anticancer drugs is one of the major 
strategies to control the disease. Anticancer drugs should be active on cancer 
cells without causing toxicity in normal tissues. However, there is a thin line 
between suboptimal treatment of the anticancer drugs and their toxicity, and 
actually anticancer drugs tend to be an aggressive treatment. The clinical use of 
these drugs contains both weighing benefits and toxicity, trying to find a 
favourable therapeutic index. Because there is a reasonable variability in 
human response to anticancer drugs, this can happen by inter-individual 
variability in drug absorption, distribution, metabolism and excretion 
(pharmacokinetics) or by differences in the sensitivity of target tissues 
(pharmacodynamics). Both the genetic status of the tumour and the genetic 
profile of the patient can influence the individual effect and safety of the drugs 
used. [7] 
The differences between individuals in drug metabolism may be 
associated to demographic factors such as gender, age, pregnancy. Drug 
metabolism and clearance of drugs can be greatly affected by drug-drug 
interactions or pathological alteration such as hepatic, renal and cardiac 
diseases. [7] 
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1.2. Drug metabolism and clearance  
 
The most important removal pathway of xenobiotics from the organism is 
through biotransformation, which usually happens in the liver. Because of this 
process, the water solubility of these substances increases and their elimination 
from the organism becomes easier through urine or bile. [7]  
These reactions can be divided into three phases. The schematic 
illustration of phases I, II, and III of xenobiotic substance materialization is 
presented in Figure 7.  
 
Figure 7. Schematic illustration of phases I, II, III of xenobiotic metabolizing systems. (adapted from [10]) 
 
Phase I reactions (also known as functionalization reactions) involve 
oxidations (e.g., hydroxylation and deamination), reductions (e.g., addition of 
hydrogen atoms), and hydrolysis (e.g., splitting of ester and amide bonds). 
Phase II reactions (also known as conjugation reactions) involve the 
conjugation of the drug with hydrophilic endogenous substrates. [7] 
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The purpose of these two main phases (I and II) during drug metabolism is 
to change the structure and inactivate the drug, facilitating its elimination from 
the body through urine or faeces in phase III. [11] 
Nearly all drugs and their metabolites are eventually eliminated from the 
body in urine or in bile. Generally, drugs with less molecular weight, water 
soluble, and that have been slowly bio–transformed slowly, are eliminated in 
urine, however drugs with high molecular weight (>500 Da) are eliminated in 
bile. [7] 
The transformation of drugs in Phase II involves conjugation of a drug or 
metabolite, initially transformed in Phase I, with endogenous substrates. These 
reactions include acetylation, amino acid conjugation, glucuronidation, sulfate 
conjugation and glutathione conjugation. The kidneys can successfully excrete 
these Phase II hydrophilic conjugates. [11]  
The enzymes catalysing these reactions are known as drug metabolizing 
enzymes (DME). [7] 
 
1.2.1. Estrogen metabolism and breast cancer 
 
Lately, much attention has been given to the effect of estrogens on breast 
carcinogenesis, since a number of risk factors are associated with endogenous 
estrogen levels, suggesting that estrogens have an important role in breast 
cancer. [12]  
Many different biological effects such as female sexual differentiation and 
development, arterial vasodilation, the maintenance of bone density, and 
neuroprotective actions are regulated by estrogens. Most of these effects result 
from direct interaction between estrogen and the estrogen receptor (ER), which 
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activates the expression of target genes encoding proteins with important 
biological functions. However, estrogens also contribute to the development and 
evolution of breast cancer. Exposure to estrogens continuously is considered a 
crucial etiological factor for the induction of estrogen-associated cancers. [13] 
Estradiol and estrone are the main estrogens circulating in the human 
body, as well as 16-hydroxyestradiol (estriol). Estriol is usually the most 
concentrated estrogen present in pregnant women, and also in the urine of all 
women, however, estradiol is the most biologically active estrogen, primarily 
secreted by ovarian granulosa cells regulated by follicle-stimulating hormone 
(FSH). [12] 
The elimination of estrogens from the body occurs by metabolic 
transformation to estrogenically inactive metabolites that are excreted in the 
urine and/or faeces. The metabolism of estrogens involve oxidation (mainly 
hydroxylation) by cytochrome P450s (CYPs), glucuronidation by UDP-
glucuronosyltransferase, sulfation by sulfotransferase, and O-methylation by 
catechol O-methyltransferase (COMT). The first step in the metabolism of 
estrogens, hydroxylation, is mediated by CYP enzymes. CYP1, CYP2, and 
CYP3 are three families that primary catalyse the oxidative metabolism of 
exogenous and endogenous compounds. Some isoforms in these CYP families 
are also responsible for the metabolism of estrogens. Because most CYP 
isoforms are mainly expressed in liver, the metabolism of estrogens occurs 
mainly in this organ. [13] 
The expression level of the estrogen-metabolizing CYP enzymes is 
controlled by many factors in the liver and target tissues. The metabolism of 
estrogen not only alters the intensity of its action but may also change the 
profile of its physiological effects in target tissues. [13] 
INTRODUCTION 
       
17 
 
1.2.2. Cytochrome  P450s 
 
Cytochromes P450 (CYP) enclose a complex family of isoenzymes, which 
are involved in drug metabolism (phase I enzymes), and are present in different 
tissues, mainly in the liver and intestine. [11] 
In order to inactivate (or activate) drugs and toxic combinations they are 
able to catalyse the oxidative biotransformation for most of the drugs and other 
xenobiotics, therefore they also play a pivotal role in clinical pharmacology also. 
[13] CYP1, CYP2, CYP3 and CYP19 are the four most distinguished P450 
families, which are involved in metabolism of anticancer drugs, and other 
xenobiotics. [11] 
The classification of CYPs is based on their amino acid sequence into 
gene families and subfamilies. The enzymes in families 1-3 participate in 
xenobiotics metabolism, while the others mostly metabolize endogenous 
compounds (e.g. steroids, bile acids, cholesterol). [7] 
 
CYP3A4, CYP2D6 and CYP2C9 dominate drug metabolism.  CYP3A4 
(CYP belonging to family 3, subfamily A) has the widest substrate specificity 
and is the most abundant CYP in the body. It has been estimated that CYP3A4, 
CYP2D6 and CYP2C9 are respectively involved in the metabolism of about 50, 
25 and 15% of clinically used drugs. [7] 
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1.2.3. Drug transporters  
 
Drug-metabolizing enzymes (DMEs) and transporters play very important 
roles in the detoxification of many unknown and endogenous chemicals. [14] 
Accumulation of carcinogens, environmental pollutants, therapeutic drugs or 
any other kind of xenobiotics in the body can affect human health. The 
detoxification of these chemicals, involve four main stages: 
 absorption/permeability,  
 distribution,  
 metabolism and  
 excretion. 
These stages are mediated by a large number of DMEs and transporters. [15] 
Drug absorption, delivery and their secretion across biological membranes 
profoundly affect the pharmacokinetics, which in its turn are affected by the drug 
transporters. [11]   
Functionally, transporters are proteins that eliminate endogenous 
compounds (such as bile acids, lipids, sugars, amino acids, steroids, hormones, 
and electrolytes) and xenobiotics (such as drugs and toxins) through the 
biological membranes in order to control the cellular and physiologic 
concentrations and to keep the fluid balance. Therefore, they support as a 
better mechanism for detoxification of any dangerous foreign substances in 
cells. Also, transporter proteins can influence drug absorption in the small 
intestine and drug elimination in the liver and/or kidney, conducting these 
substances in and out of the intestinal enterocytes, hepatocytes, or renal tubular 
cells.  Another important role of transporters is to limit the penetration of drugs 
into brain, placenta, tumour, T-cells, and others. The reduction in the 
transporter’s functions can increase the toxicity. [16] 
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The ABC transporters (ATP-Binding Cassette transporters) contain a 
family of transmembrane proteins which use ATP hydrolysis as a power source 
for transport activity. Seven major subfamilies of the ABC transporters genes 
exist, however, only three of them (ABCB, ABCC, ABCG) are engaged in drug 
transport including anticancer drugs. [11] 
The ABCB1 (MDR1/P-glycoprotein), ABCC (MRP), and ABCG2 
(MXR/BCRP) are active transporters and have a main interest to 
pharmacologists since they are responsible for both the uptake and the efflux of 
drugs and are essential elements of the pharmacokinetic characteristics of a 
drug. However, it has now become clear that transporters are crucial for the 
uptake, accumulation, distribution and efflux of drugs. For example, drug efflux 
transporters including the P-glycoprotein pump (Pgp), the multidrug-resistant 
protein-1 (MRP1) and the BCRP actively pump drugs such as 
chemotherapeutics out of the cells, therefore are used for reducing their 
intracellular accumulation and making the cell insensitive to different drugs.  
Among the major known ABC transporters, ABCB1 gene, also known as 
MDR1, encoding Pgp is by far the best characterized and understood efflux 
transporter. Pgp plays an important role in limiting intestinal drug absorption and 
brain penetration as well as in facilitating renal or biliary excretion of drugs. The 
MRPs are involved in the drug efflux from the liver or kidney into the peripheral 
blood (e.g. MRP1, MRP3, and MRP6), or from the liver, kidney and small 
intestines into the bile urine and intestinal lumen respectively (MRP2). [17] 
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1.2.4. Regulation of expression 
 
The inter-individual variability in drug metabolism and transport is due to 
genetic factors or to variable expression of the relevant genes in different 
physiological or pathological circumstances. Several xenobiotics and 
endobiotics are known to change expression of target genes, mainly by 
regulating the rate of transcription.  An essential concept about gene expression 
in the disease state, and the effects of xenobiotics or any other foreign 
pollutants, is that often the events observed are cell-, species-, sex-, and 
development-specific. This is due to the fact that combinational gene 
expression is typical of eukaryotes. Generally, a combination of multiple gene-
regulatory proteins, rather than a single protein, decide where and when a gene 
is transcribed. A single gene may be essential but not enough to change the 
phenotype of a cell. [18] 
A key component of many complex phenomena including cellular 
development, differentiation, maintenance, and injury or death is the differential 
gene expression. The subgroup of genes which are expressed determines the 
phenotype of that cell. Also, a failure of control of differential gene expression 
determines many disease states, including cancer. The understanding of the 
function of these genes can be helpful in the identification of genes that are 
being expressed in one cell type versus another (i.e., control versus treated; 
tumour versus normal). Therefore, the identification of differentially expressed 
genes has been followed for different influences such as responses to biological 
programs, physical agents (i.e., UV irradiation, X-rays), and chemical agents 
(hormones and xenobiotics). [18] 
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1.3. Nuclear receptors 
 
Drug-metabolizing enzymes (DMEs) and transporters play a central role in 
the metabolism and clearance of xenobiotics. To face chemical challenges, the 
expression of many DMEs and transporters is controlled by a group of ligand-
activated transcription factors designated as nuclear receptors (NRs). [14]  
 
 
1.3.1. The identification of Nuclear Receptor 
 
The first NR was identified biochemically in the 1960s by Ron Evans and 
co-workers Pierre Chambon and Geoffrey Greene. Since then, NRs have 
become identified as a superfamily of transcription factors, and the NR research 
field has grown very fast and covers areas ranging from structural and 
functional analyses to the molecular mechanisms of transcription regulation. 
[19] . To date, 48 NRs have been recognized in humans (Table 1). [20] 
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Table 1. List of mammalian Nuclear Receptor (taken from [20]) 
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1.3.2. Structure of Nuclear Receptors 
 
All the nuclear receptors have common structural characteristics (Figure 
8), which contain a central DNA binding domain (DBD) responsible for targeting 
the receptor to highly specific DNA sequences. The ligand binding domain 
(LBD) is involved in the C-terminal half of the receptor and recognizes specific 
hormonal and nonhormonal ligands directing specificity to the biologic 
response. These receptors contain variable N-terminal and C-terminal domains, 
as well as a variable length hinge region between the DBD and LBD. [21] 
 
 
Figure 8. Structure and functional domains of the nuclear receptors (adapted from [22]) 
 
 
1.3.3. The role of Nuclear Receptors 
 
Nuclear receptors regulate specific target genes involved in different 
functions of the body, such as homeostasis, metabolism, development, 
reproduction and other physiological processes. [20,23] 
NRs are members of a superfamily of ligand-regulated (and orphan) 
transcription factors that transduce different endocrine hormones such as 
steroid, retinoid, thyroid, and lipophilic into specific physiological responses. [24] 
NRs were identified as receptors for their cognate ligands and they primarily 
function as ligand-activated DNA-binding transcription factors. As transcription 
factors, NRs regulate directly the expression of hormone response genes. 
INTRODUCTION 
24 
 
There are different functions associated with different kinds of hormone 
receptors, e.g., the progesterone (PR), androgen (AR), and estrogen (ERα and 
ERβ) receptors operate in reproduction and target tissue growth; the thyroid 
hormone receptors (TR) control oxidative metabolism; the glucocorticoid 
receptor (GR) regulates glucose metabolism, inflammation, and stress; and 
peroxisome proliferator-activated receptors (PPARs) have central roles in 
regulating energy and lipid metabolism. [24] 
Nuclear receptors regulate specific target genes involved in metabolism, 
development reproduction and other physiological processes. [19] The 
significance of NRs in xenobiotic metabolism and clearance is best 
demonstrated by xenobiotic receptors: pregnane X receptor (PXR, NR1I2). [14] 
 
 
 
1.3.4. Characteristics of PXR 
 
Xenobiotics including drugs and environmental chemicals have a very 
negative impact on human health. [14] Therefore the nuclear pregnane X 
receptor (PXR; NR1I2) is an important component of the body’s protection 
mechanism against toxic substances including foreign chemicals. PXR is 
activated by a large number of endogenous and exogenous chemicals including 
steroids, antibiotics, antimycotics, bile acids, and the herbal antidepressant. [25] 
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1.3.5. Structure of PXR 
 
Pregnane X receptor (PXR), also known as the steroid and xenobiotic 
sensing nuclear receptor (SXR) or nuclear receptor subfamily 1, group I, 
member 2 (NR1I2) is a protein that in humans is encoded by the NR1I2 (nuclear 
receptor subfamily 1, group I, member 2) gene. [26] The pregnane X receptor is 
an approximately 434- amino acid, 50-kDa protein, primarily expressed in the 
liver and intestine. [14] 
The PXR protein contains a DNA-binding domain (DBD), a hinge region 
(H), a ligand-binding domain (LBD) a ligand-dependent transactivation function 
2 (AF-2) (Figure 9). PXR does not have a ligand-independent activation 
function 1 domain (AF-1), in comparison with other nuclear receptors.  PXR is 
an orphan nuclear receptor that is activated by binding to various chemically 
and structurally distinct endobiotics and xenobiotics including clinically-used 
chemotherapeutic drugs (tamoxifen, doxorubicin, taxol, and vincristine) and 
environmental chemicals. [27] 
 
 
Figure 9. Schematic comparison of the domain structures of a typical nuclear receptor and PXR. AF‑1, 
activation function-1; DBD, DNA-binding domain; H, hinge region; LBD, ligand-binding domain; AF‑2, 
transactivation function-2; PXR, pregnane X receptor (taken from [28]) 
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1.3.6. Distribution of PXR 
 
PXR is mainly expressed in the liver, small intestine and colon in humans. 
PXR is expressed not only in normal tissues, but also in numerous types of 
human cancer, including breast, osteosarcoma, colon, endometrial, ovarian, 
prostate and esophageal cancers. Most significantly, the expression levels of 
PXR in these cancer tissues are usually higher than in non‑neoplastic tissues. 
[28] 
PXR co-ordinately regulates a large proportion of genes and proteins in 
the liver, intestine and other organs that are involved in all aspects of the 
detoxification and elimination of xenobiotics and drugs. [28] 
 
 
 
1.3.7. Function of PXR 
 
The pregnane X receptor (PXR) is a nuclear receptor which main function 
is to sense the presence of foreign toxic substances (e.g. xenobiotics), and in 
response regulates the expression of proteins involved in the detoxification and 
clearance of these substances from the body. [25]  
 PXR is the main transcriptional regulator of many enzymes that 
metabolize xenobiotics, such as P450s, and drug transporters (Figure 10). PXR 
is a member of the nuclear receptor superfamily of ligand activated transcription 
factors that controls the expression of their target genes by binding to the 
gene’s promoter. [27] 
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Figure 10. hPXR mediated induction of drug metabolizing enzymes of phases I,II and III (taken from [29]) 
 
 
1.3.8. PXR and drug metabolism 
 
The human Pregnane X Receptor (hPXR) is the master transcription factor 
for cytochrome P450 3A4 (CYP3A4) and multidrug resistance protein 1 
(MDR1). The hPXR is able to be activated by structurally different ligands. [30]  
Many steps in xenobiotic metabolism can be regulated by PXR in 
collaboration with other nuclear receptors such as:  
 constitu-tive androstane receptor (CAR),  
 aryl hydrocarbon receptor (AhR),  
 peroxisome proliferation activated receptor α and γ (PPAR),  
 liver X receptor (LXR),  
 farnesoid X receptor (FXR), and  
 vitamin D receptor (VDR). 
 
hPXR is able to regulate the expression of the main  phase I DMEs, such 
as CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4/5, and CYP3A7; 
therefore, involving about >60% metabolism of endobiotics and xenobiotics. It 
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also organizes phase II DMEs such as UGT (Uridine-diphospho-
glucuronosyltransferase), sulfotransferase, acetyltransferase, 
methyltransferase, and glutathione-S-transferase, as presented in Figure 11. 
hPXR also can cause the  stimulation of phase III efflux transporters of ABC 
(ATP binding cassette) superfamily, such as Pgp (p-glycoprotein), BCRP 
(breast cancer resistance protein), and MRP (multiple resistance drug protein). 
[30] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. hPXR mediated induction of drug metabolizing enzymes, transporter and their role in drug 
interaction. Abbreviations: PXR, pregnane X receptor; RXR, retinoid X receptor; DNA, deoxyribonucleic 
acid; mRNA, messenger ribonucleic acid; MRP, multiple resistance drug protein; MDR, multidrug 
resistance protein; BCRP, breast cancer resistance protein; CYP3A4, cytochrome P-450 monooxygenase 
3A4; CYP2B6, cytochrome P-450 monooxygenase 2B6; UGTs, uridine 5’- diphospho- 
glucuronosyltranferases; SULTs, sulfotransferases; GSTs, glutathione-S-transferases; ALDHs, aldehyde 
dehydrogenases (taken from [30]) 
 
 
The cytochrome P450 CYP3A4 and the ATP binding cassette (ABC) 
transporter P-glycoprotein (Pgp) are two main factors that regulate the exposure 
to a large range of xenobiotics. The transcription of the corresponding genes 
CYP3A4 and multidrug resistance (MDR1) is activated by xenobiotics through 
activation of at least one common nuclear receptor, the PXR. [31] 
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1.3.9. PXR  and Chemotherapy  
 
One of the most common treatments for cancer is chemotherapy. 
However, due to multidrug resistant cancer cells, the efficiency of this treatment 
is narrow or limited. However drug metabolizing enzymes (DMEs) and efflux 
transporters can help in promotion of the metabolism, excretion, and 
detoxification of chemotherapeutic agents. Due to this, high levels of DMEs and 
efflux transporters, decrease the efficacy of chemotherapeutics and usually may 
cause failing of the therapeutic treatment.  During chemotherapy, nuclear 
receptors, in particular pregnane X receptor (PXR, NR1I2) and constitutive 
androstane activated receptor (CAR, NR1I3), are known  for their pivotal role in 
metabolism and clearance of xenobiotic and also for their importance in the 
development of multidrug resistance (MDR). [15] 
Multidrug resistance (MDR) is an important barrier to the pharmacokinetics 
and pharmacodynamics of anticancer drugs, mostly as a result of the induction 
potential of anticancer drugs for drug metabolizing enzymes (DMEs) and efflux 
transporters through nuclear receptors. [30] 
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1.3.10. Pharmacogenetics of PXR polymorphisms 
 
Single nucleotide polymorphism (SNP) is an inherited change in the DNA 
sequence, usually substituting one nucleotide for another (Figure 12). [7] 
 
 
 
 
 
 
 
 
Figure 12.  Genotyping looks at single letter substitutions in the genetic code. These genetic variation are 
called Single Nucleotide Polymorphism (SNPs). [32] 
 
 
A single nucleotide polymorphism (SNP) is a nucleotide variation at a 
specific location in the genome. Typically, SNPs are bi-allelic and by definition 
found in more than 1% of the population. In practice, tri- or tetra-allelic SNPs, 
insertions, deletions and variations found in less than 1% of the population are 
also considered as SNPs. SNPs are the most abundant variations in the human 
genome. [33] 
Like mutations, SNPs can cause changes within a gene (coding SNP), 
predicted to change an amino acid (a non-synonymous SNP). Rather, the SNP 
can change a nucleotide within a gene, which is not predicted to change an 
amino acid (a synonymous SNP). [7] 
Single nucleotide polymorphisms (SNPs) are used as markers in linkage 
associated to studies to detect which regions in the human genome may be 
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involved in diseases. SNPs in coding and regulatory regions may be involved in 
disease themselves. In the main interest are non-synonymous SNPs, which 
cause an amino acid change in the protein product, and these amino acid 
substitutions are considered to be responsible for approximately half of the 
known gene lesions responsible for human inherited disease. [34] 
Related to this argument, as we mentioned above in the drug metabolism 
and clearance section, the effectiveness of the steps in drug metabolism, as 
well as the host response to the drug treatment is mainly dependent on the 
genetic polymorphisms in the drug metabolizing enzymes, patients' age and the 
health status of drug detoxifying organs. Therapy toxicity or drug resistance can 
be a result of any failure in this machinery caused by these factors, with a 
special distinction of SNP genotypes present in the drug responsive genes. 
Also, genetic polymorphisms can influence transporters causing inter patient 
differences in drug response. [11] The NR1I2 gene, which encodes PXR, 
contains 10 exons and is located on chromosome 3q13-21. Different SNPs 
have been reported in NR1I2 and some are associated with changes in PXR 
function. [35] 
To date, 227 SNPs of hPXR have been deposited in dbSNP. [36] The SNP 
that was investigated in this study, SNP NR1I2 7635A>G,  is present in intron 5 
and the 7635G allele has been associated with increased expression of 
CYP3A4 in the presence of rifampicin. [35] 
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1.4. Genotyping methods 
 
Different SNP genotyping techniques have been reported in the last years. 
One of the most common methods employed to discover novel SNPs is 
sequencing DNA fragments amplified by polymerase chain reaction (PCR). 
PCR primers are designed to amplify both strands of DNA from genes or other 
single copy genomic sequences (Figure 13). PCR products are sequenced, 
allowing for novel SNP identifications. [33] 
 
Figure 13. General steps in a PCR procedure (taken from [37]) 
 
Since the invention of PCR by Karry Mullis in the 1980s, the application of 
the PCR method has provided great contributions in molecular genetic 
research. This simple and sensitive enzymatic technique for the amplification of 
DNA fragments has been used for many different purposes, but especially for 
the detection of nucleic acid polymorphisms in order to find the biological 
significance in genetic variation and molecular divergence in living organisms. 
[38] 
Denaturation 
Annealing 
Elongation 
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The majority of polymorphisms in the human genome are SNPs, which are 
considered for more than 90% of sequence variations, and are applied as an 
important tool for the study of the structure and history of our genome. There 
are more than 27 million SNPs in the human genome that have been recorded 
in a database. This immense amount of data contribute with important 
information for SNP-based studies, identification of candidate genes involved 
with complex genetic diseases, pharmacogenetic analysis, drug development, 
population genetics, evolutionary studies and forensic investigations. In the last 
twenty years, many different methods have been developed for SNP genotyping 
by PCR, including hybridization, allele-specific PCR, primer extension, 
oligonucleotide ligation, direct DNA sequencing and endonuclease cleavage, 
after amplification of the subjected genomic region by PCR. Recent methods for 
SNP genotyping, such as Taqman method, Invader, MALDI-TOF and 
GeneChips have high performance; however, they are relatively expensive. The 
PCR technique has evolved for better understanding of the causes of genetic 
variants and mutations. Polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) is a technique applied on the detection of single 
nucleotide polymorphisms (SNPs).  PCR-RFLP allows a fast detection of point 
mutations after the genomic sequences is amplified by PCR. The mutation is 
discriminated by digestion with specific restriction endonucleases and is 
identified by gel electrophoresis after staining with ethidium bromide (EtBr) or 
other fluorescent indicator, such as Green Safe. [38] 
PCR-RFLP is a simple, relatively inexpensive and precise method for SNP 
genotyping, and especially helpful in small basic research studies of complex 
genetic diseases. It is based on endonuclease digestion of PCR-amplified DNA. 
The specific restriction endonuclease recognizes and cleaves the DNA in the 
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region of the point mutation of the PCR products. The SNP type is easily 
identified by using gel electrophoresis to confirm and separate the sizes of the 
smaller DNA fragments generated by the endonuclease digestion. This method 
is available for genotyping not only a SNP but also insertion/deletion 
polymorphisms, and multiple mutations [38] 
 
 
1.4.1. Genotype and allele 
 
In the living cell, genes are organized in linear order along microscopic 
threadlike bodies called chromosomes. A typical chromosome may consist of 
several thousand genes. The position of a gene along a chromosome is called 
the locus of the gene. In higher organisms, each cell has two copies of each 
type of chromosome. Such organism, in which the chromosome are present in 
pairs, are said to be diploid. In each pair of chromosomes, one member is 
inherited from the mother through the egg and the other is inherited from the 
father through sperm.  At each locus, accordingly, diploid organism contains two 
alleles, one each at corresponding positions in the maternal and paternal 
chromosomes. If the two alleles at a locus are chemically identical (in the sense 
of having the same nucleotide sequence along the DNA), the organism is said 
to be homozygous at the locus under consideration; if the two alleles at a locus 
are chemically different, the organism is said to be heterozygous at the locus. 
The term gene is a general term usually used in the sense of locus. Geneticists 
make an essential differentiation between the genetic structures of an organism 
and the physical or biochemical attributes of the organism. The genetic 
structure of an organism is called genotype; genotype thus refers to the 
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particular alleles present in an organism at all loci that affect the trait in 
question. [39] 
 
 
1.5. Observational Studies 
 
Observational studies are a fundamental part of epidemiology and account 
for many of the research papers published in specialty research journals. We 
can apply epidemiology to study any specific population. In epidemiology is 
assumed that health, disease, and illness are not random, and there are 
characteristics that protect us and that predispose us to harm, different 
diseases, and other occurrences. These characteristics may be genetic, 
environmental exposures, or other factors. Typically, the distributions of 
characteristics or events are evaluated, or possible associations between 
certain characteristics and health outcomes are investigated. [40] 
 
 
1.5.1. Case-Control Studies 
 
A case–control study is an observational study in which study subjects are 
chosen who meet a “case” definition (e.g. individuals with breast cancer) and 
also subjects that decidedly are not “cases” (e.g. individuals without any 
neoplastic disease). Case–control studies are typically retrospective studies 
because the approach is to identify persons with the disease of interest and 
then look backward in time to identify factors that may have caused it. Possible 
associations between the disease of interest and one or more hypothesized risk 
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factors are analysed in case-control-studies. The general strategy is to compare 
the frequency or level of potential risk factors between a representative group of 
diseased subjects, or cases, and a representative group of disease-free 
persons, or controls, derived from the same population. Three important criteria 
for case–control studies help to minimize the potential for bias: [40] 
 The selection of cases must be representative of all patients who develop 
the disease.  
 The controls must be representative of the general healthy population who 
do not develop the disease. 
 The information must be collected from cases and controls in the same 
way.  
 
Case–control studies that require invasive procedures for diagnosis 
typically cannot expose controls to the risk of these procedures unless indicated 
clinically (e.g. coronary angiography or tissue biopsy). As in all other 
observational study designs, it is important to have as high a participation rate 
as possible to minimize biases resulting from nonresponse. Cost and 
accessibility should be considered when selecting controls because it is 
generally more difficult to motivate disease-free persons to join a study than 
those with disease who have a strong interest in determining its cause. The 
validity and reproducibility of measurement techniques in both cases and 
controls should be established or assessed during the study. Observations from 
case–control studies are frequently presented in a “2 × 2” table with the 
exposure status in rows and the case–control status in columns (Table 2). Cell 
“A” represents the number of exposed cases, cell “B”, the number of exposed 
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controls, and the row total, “A + B”, all exposed subjects. Column totals “A + C” 
and “B + D” are the numbers of cases and controls, respectively. [40,41] 
 
Table 2. Presentation of Findings in a “2 × 2” Contingency Table. 
 
 
 
1.5.2. Chi-Square Test of Contingency  
 
Testing a contingency table assesses the independence between 
categories in rows and columns. Independence implies that the variables in the 
rows are not related to the variables in the columns. Dependence implies the 
existence of association. However, this does not provide information about the 
strength of this association. The strength of association can be assessed by the 
means of odds ratios, which is described in the next section. The chi-square 
test of contingency is based on the differences between the observed values 
and those that would be expected if the variables were independent. If these 
differences are small, there is little dependence between the variables, whereas 
large differences indicate dependence. The expected values are calculated by 
multiplying the corresponding row sum by the column sum, divided by the total 
sum (N). In general, for row i and column j, the expected value of the ijth entry is 
given by equation 1. The expected values calculated from the observed values 
in Table 2 are represented in Table 3. The chi-square statistic is the sum of 
Total
Present A B A+B
Absent C D C+D
Total A+C B+D N
Number with 
disease
Number without 
disease
Presence of Disease
Exposure
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squares of these differences in ratio to the expected value (equation 2). A small 
chi-square statistic arises if the observed values are close to the values we 
would expect if the two variables were unrelated. A large chi-square statistic 
arises if the observed values are rather different from those we would expect 
from unrelated variables. [41] 
 
       Eij=
ni×nj
N
    (1) 
 
   χ2= ∑
(Oi-Ei)
2
Ei
i    (2) 
 
 
Table 3. Expected Values from a “2 × 2” Contingency Table. 
 
 
 
1.5.3. Odds Ratio  
 
Odds ratio (OR) is a measure of the strength of association between an 
exposure factor (risk factor) and an event (disease). In observational studies, it 
represents the ratio between the odds for the occurrence of an event in a group 
exposed to a factor and the odds for the occurrence of the same event in a 
group exposed to a different factor (or not exposed). The calculation of the odds 
ratio is obtained with equation 3, where the values A, B, C, D are the observed 
Present (A+B)(A+C)/N (A+B)(B+D)/N
Absent (C+D)(A+C)/N (C+D)(B+D)/N
Exposure
Presence of Disease
Number with 
disease
Number without 
disease
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cases from Table 2. The confidence interval with 95% confidence level for the 
odds ratio is given by equation 4. [41,42] 
 
     OR=
A
B⁄
C
D⁄
   (3) 
 
exp [ln(OR)±1.96√
1
A
+
1
B
+
1
C
+
1
D
]  (4) 
 
 
 
1.6. Objectives of the study  
 
 
Given that estrogens are a well-established risk factor for breast cancer, 
and that these molecules are metabolized mainly by CYP3A4, it is conceivable 
that variations in CYP3A4 activity may be associated with individual 
susceptibility for the disease. Since PXR is the major transcriptional regulator of 
CYP3A4 expression, we hypothesized that variability in PXR may contribute to 
inter-individual variability in risk. As such, in this work, we aimed at evaluating 
the existence of an association between the PXR 7635 SNP and risk of 
disease, in a case-control study for breast cancer in the Portuguese population. 
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2. EXPERIMENTAL 
 
2.1. Patients and Method 
 
The A7635G polymorphism of PXR was investigated in a case-control 
study in a sample of the Portuguese population. Blood samples were obtained 
from 100 female patients with breast cancer, and from 114 female individuals 
without any neoplastic disease, recruited by the Research Unit in Human 
Molecular Genetics, Lisbon, Portugal.  
Written consents were obtained from all individuals before the blood 
analysis. This study was approved by the ethical boards of the involved clinical 
institution and followed the recommendations of the Declaration of Helsinki, 
promulgated in 1964.  
DNA extraction and genotyping were performed in the Laboratory of 
Pharmacogenomics and Molecular Toxicology, Centre for Biomedical Research 
(CBMR), University of Algarve. The genotyping was performed by means of 
PCR–RFLP. 
 
 
2.2. Data treatment 
 
PXR allelic and genotypes frequencies in individuals with and without 
breast cancer with 95% confidence intervals (CI) were assessed using the Chi-
square (χ2) testing which was performed using Microsoft Office Excel 2010. 
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3. RESULTS AND DISCUSSION  
 
3.1. Genotype and Allele frequencies 
 
The presence of the polymorphism A7635G was investigated in breast 
cancer patients and its frequency compared with that found in healthy 
individuals, in order to evaluate its potential association with individual risk. The 
A7635G polymorphism in PXR was obtained from 100 female patients with 
breast cancer, and from 114 female individuals without any neoplastic disease 
in a sample of the Portuguese population. The PXR genotype and allele 
frequencies are represented in Figure 14. 
 
 
Figure 14. Frequencies of PXR7635 genotypes and alleles in 100 individuals with breast cancer 
and 114 individuals without any neoplastic diseases. 
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3.2. Chi square analysis 
 
The chi-square and p-values access the significance in the association 
between the disease and the genotypes and alleles studied. The expected 
values, calculated from the observed cases using a contingency table (Table 3) 
and equations 1 and 2, and are presented in Table 4 in. These results are also 
displayed in a Chi-square distribution function (Figure 15). 
 
Table 4.  Contingency tables (2x2) with the observed cases the calculated expected values, Chi 
square and p-values (calculated in Excel).  
 
 
 
Figure 15. χ
2
  and p-values of the genotypes and alleles association with the Breast Cancer 
disease, represented in a χ
2
 distribution with one degree of freedom. 
Breast Cancer Controls Breast Cancer Controls
27 47 34.6 39.4
73 67 65.4 74.6
60 52 52.3 59.7
40 62 47.7 54.3
13 15 13.1 14.9
87 99 86.9 99.1
114 146 121.5 138.5
86 82 78.5 89.5
86 82 78.5 89.5
114 146 121.5 138.5
0.1372.21
4.42 0.036
0.9730.00
2.21 0.137
With Genotype A/A
With Genotype A/G
Without Allele A
With Allele G
Without Allele G
OBSERVED VALUES 
Without Genotype A/A
Without Genotype A/G
Without Genotype G/G
With Genotype G/G
With Allele A
4.77 0.029
χ2 (1 d.f.) p-value
EXPECTED VALUES
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3.3. Odds ratio 
 
The odds ratios and the confidence intervals with 95% confidence level 
were calculated using equations 3 and 4 respectively. These results are 
presented in Table 5 and displayed in Figure 16. 
 
Table 5. Genotypic and allelic frequencies of PXR7635 in individuals with Breast Cancer and 
individuals without any neoplastic diseases, Odds Ratios, and p-values of the Chi-Square 
distribution with one degree of freedom. 
 
 
 
 
Figure 16. Odds ratios and confidence intervals (95% confidence level) of the associations 
between individuals with each genotype and allele and the Breast Cancer disease. 
 
 
 
 
A/A 27.0 41.2 27 47 0.029 0.53 0.296 - 0.940
A/G 60.0 45.6 60 52 0.036 1.79 1.038 - 3.081
G/G 13.0 13.2 13 15 0.973 0.99 0.445 - 2.187
Total 100 114
A 57.0 64.0 114 146 0.137 0.74 0.504 - 1.099
G 43.0 36.0 86 82 0.137 1.34 0.910 - 1.982
Total 200 228
OR
Confidence Interval 
(95%)
p-value
Alleles
 Genotypes
Breast Cancer 
(%)
Controls          
(%)
Breast Cancer 
(N)
Controls          
(N)
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3.4. Interpretation of results 
 
The associations of the genotypes A/A and A/G with the disease are 
significant (p < 0.05); on the other hand, and according to the results, the 
genotype G/G and the alleles A and G have no association with the disease, 
with a 95% level of confidence. Small χ2 values and large p-values indicate that 
the observed and expected cases are not significantly different, and there is a 
large probability of a case occurring by chance alone (p > 0.05), whereas, large 
χ2 values and small p-values indicate that the observed and expected cases 
are significantly different, and there is a small probability of a case occurring by 
chance alone (p < 0.05). 
The odds ratios provide information on the kind of association existing 
between the presence of the genotypes or alleles with the disease. As observed 
in Figure 16, the odds ratio for the genotype A/A is lower than the critical value 
of 1, and also its confidence interval, which represents a negative association 
between this genotype and the disease. 
The odds ratio regarding genotype A/G is higher than the critical value, 
including the 95% confidence interval, which represents and positive 
association with the disease. The genotype G/G has an odds ratio very close to 
one, which means no association, either positive or negative, and considering 
the alleles A and G individually, they appear to have negative and positive 
association respectively; however, the 95% confidence intervals make these 
assumptions inconclusive. 
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4. CONCLUSIONS 
 
According to the results obtained from the investigation of patients with 
breast cancer compared with control cases study, we can conclude: 
 
 The associations of the genotypes A/A and A/G with the disease are 
statistically significant with 95% confidence level (p < 0.05). The 
genotype G/G and the alleles A and G considered individually have no 
significant association with the disease, with a 95% level of confidence. 
 Individuals with genotypes A/A have low risk of having breast cancer 
disease (OR = 0.53, CI=[0.296 - 0.940], 95% CL), whereas the ones with 
genotype A/G have high risk to contract the disease (OR = 1.79, 
CI=[1.038 - 0.940], 95% CL). 
 Individuals with genotype G/G have no association with the disease (OR 
= 0.99, CI = [0.445-2.187], 95 CL), since it’s very close to OR = 1. 
However, with the confidence interval, both positive and negative 
associations can be possible with 95% confidence level.  
 Considering the alleles, positive and negative associations are verified 
with the odds ratios. However, this conclusion is affected by the 
confidence intervals. Therefore it is inconclusive, like for genotype G/G.  
 
. 
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5. COMMENTS AND FUTURE WORK  
 
Lately, in the last 16 years, after many studies about hPXR, the pivotal 
role in the activation of cytochromes P450s and efflux transporters leading to 
MDR in cancer is documented in the scientific literature. In view of the 
development of inhibitors and to restrain the spreading of the cancer, especially 
targeting the MDR in chemotherapeutics, the hPXR is a hopeful goal. A new 
strategy in anticancer drug development is necessary, in order to avoid the 
limitations in the present cancer chemotherapy and MDR. The hPXR is a novel 
target and its inhibitors can be used as adjuvants in the chemotherapy. [24] 
 
In the future work I would like to work in molecular biology and genetic 
molecular respectively in cancer research groups, in order to employ the 
techniques that were used in this study, and also new methods used nowadays, 
for helping the society specially women gender for the detection of breast 
cancer disease in the early stages, and to evaluate the potential role of PXR 
receptor in the susceptibility to this disease, as a hopeful goal in 
chemotherapeutics. 
 
During this study, because of my pregnancy circumstances, I was not able 
to work in the laboratory because of the presence of ethidium bromide, which is 
a dangerous chemical substance especially for my case. However I enjoyed 
searching, studying and writing  the topic of my thesis, which I think is very 
interesting and it will be helpful in the future studies too. 
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